Study #2019-0034
Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (CRC)
MD Anderson Study Status
Not Accepting
Treatment Agent
ZW25 (Zanidatamab), Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Capecitabine, Bevacizumab, Gemcitabine
Description
This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for selected gastrointestinal (GI) cancers. Eligible patients include those with unresectable, locally advanced, recurrent or metastatic HER2-expressing gastroesophageal adenocarcinoma (GEA), biliary tract cancer (BTC), or colorectal cancer (CRC).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Study phase:
Phase II
Physician name:
Jaffer Ajani
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-866-499-8634
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.